In the subpopulation of patients with asthma, BEC ≥ 150 cells/μL, and total IgE 30–700 kU/L, dupilumab showed a greater reduction in exacerbation rate and improvement in FEV1 compared to omalizumab and mepolizumab. Here, IGHE is linked to asthma.